Meeting
2020 ASCO Virtual Scientific Program
A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
Authors
Shiraj Sen
Sarah Cannon Research Institute at HealthONE, Denver, CO
Shiraj Sen , Meredith Ann McKean , Laura Sierra , Jessica Ainscough , Jay Yang , Anthony Hamlett , Tom Zimmerman , Melinda Merchant , Sant P. Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04204941
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS11573)
DOI
10.1200/JCO.2020.38.15_suppl.TPS11573
Abstract #
TPS11573
Poster Bd #
461
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).
First Author: Sant P. Chawla
Poster
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
First Author: Mrinal M. Gounder
Poster
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
First Author: Zhengfu Fan
Poster
2022 ASCO Annual Meeting
Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
First Author: Connie Lee Batlevi